Related Experiment Video

Updated: Apr 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

[Chronic hepatitis C in children: problems and prospects]

G V Volynets, A S Potapov, T A Skvortsova

    Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
    |May 15, 2015
    PubMed

    Insights

    This study analyzes chronic hepatitis C in children, detailing its incidence, diagnosis challenges, and transmission risks. It highlights current treatment issues and future prospects for managing this viral infection in pediatric populations.

    Area of Science:

    • Hepatology
    • Pediatric Infectious Diseases
    • Virology

    Context:

    • Chronic hepatitis C (HCV) poses a significant health concern in pediatric populations globally.
    • Understanding the epidemiology and clinical presentation of HCV in children is crucial for effective management.
    • Current diagnostic and therapeutic strategies for pediatric HCV require further evaluation.

    Purpose:

    • To analyze the current state of chronic hepatitis C in children.
    • To review primary incidence data and diagnostic challenges of HCV infection in pediatric populations.
    • To explore risk factors, transmission routes, clinical features, and treatment prospects for pediatric HCV.

    Summary:

    • The study examines the incidence of chronic hepatitis C in children within the Russian Federation and internationally.
    • It investigates diagnostic difficulties, contamination risks, transmission pathways, and the specific clinical course of HCV infection in children.
    • Analysis includes current treatment challenges and future directions for managing chronic viral hepatitis C in pediatric patients.

    Impact:

    • Provides a comprehensive overview of the pediatric chronic hepatitis C problem.
    • Identifies key areas for improvement in diagnosis and risk mitigation strategies.
    • Informs future research and clinical practice for treating HCV in children.

    More Related Videos

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

    Published on: February 19, 2019

    12.3K
    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

    Published on: August 29, 2025

    695

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
    59
    Cytomegalovirus Disease01:27

    Cytomegalovirus Disease

    Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
    50
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    353
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    389
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    263
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    353